Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J 
Welcome,         Profile    Billing    Logout  
 4 Diseases   6 Trials   6 Trials   725 News 


123456789»
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
    Review, Journal:  Combination of Two Long-Acting Antipsychotics in Schizophrenia Spectrum Disorders: A Systematic Review. (Pubmed Central) -  May 25, 2024   
    Policy initiatives that remove barriers to primary adherence or fulfillment may help improve patients' clinical outcomes. Our review highlights that the treatment regimen with two concurrent LAI APs is already widely used in clinical practice and is recognized as providing a promising, effective, and relatively safe therapeutic strategy for treating the schizophrenia spectrum disorders.
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
    Trial completion:  CASPAR: A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings (clinicaltrials.gov) -  May 22, 2024   
    P4,  N=93, Completed, 
    Our review highlights that the treatment regimen with two concurrent LAI APs is already widely used in clinical practice and is recognized as providing a promising, effective, and relatively safe therapeutic strategy for treating the schizophrenia spectrum disorders. Active, not recruiting --> Completed
  • ||||||||||  Abilify Maintena (aripiprazole depot formulation) / Otsuka, Lundbeck, Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
    Review, Journal:  Switching from paliperidone palmitate 3-monthly long-acting injection to oral aripiprazole in a pregnant woman with schizophrenia: a case report and short review. (Pubmed Central) -  Apr 27, 2024   
    No obstetrical or fetal complications were reported. As the research in this field is very demanding, it would be precipitous to derive final conclusions from the current case report, but we hope to build a growing number of data that would allow us to make more appropriate and safe therapeutic choices in such a vulnerable phase as the peripartum.
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
    Hypercalcemia related to Paliperidone in ESRD patient () -  Mar 23, 2024 - Abstract #NKFSCM2024NKF_SCM_682;    
    58 year-old male with diabetes,schizo affective disorder,ESRD on hemodialysis had hypercalcemia on monthly dialysis labs.Being on dialysis for a year,his mineral bone disease was well controlled without requiring any phosphate binders or calcimimetics.Home meds were insulin,ability and benztropine.Due to uncontrolled schizoaffective disorder,monthly paliperidone injection was started which helped his symptoms remarkably.Within few months of starting paliperidone,we noted a strange association of hypercalcemia,which couldn't be explained otherwise.Calcium stayed above 10.5 mg/dl the week or following week of getting injection paliperidone while it normalized 3-4 weeks later.PTH levels were between 300-450 while his phosphorus stayed in range 3.5-4.5.Hypercalcemia workup for malignancy,paraproteinemia,Vit D intoxication,granulomatous disorders were negative.He wasn't on calcium-based binders or calcium supplement nor taking common hypercalcemia causing drugs like thiazide or lithium.He was not limited by mobility.His prolactin was elevated at 192. Hypercalcemia workup should include atypical antipsychotics drugs in schizoaffective ESRD patients.
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
    Journal:  Mining oomycete proteomes for phosphatome leads to the identification of specific expanded phosphatases in oomycetes. (Pubmed Central) -  Mar 15, 2024   
    To delve further into its function, we generated knockout mutants of PPM1 and validated its essential roles in mycelial growth, sporangia and oospore production, as well as infectious stages. To the best of our knowledge, this study provides the first comprehensive inventory of phosphatases in oomycetes and identifies an important phosphatase within the expanded serine/threonine phosphatase group in oomycetes.
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Hafyera (paliperidone palmitate extended-release 6-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
    Review, Journal:  Evaluating the 6-month formulation of paliperidone palmitate: a twice-yearly injectable treatment for schizophrenia in adults. (Pubmed Central) -  Mar 12, 2024   
    PP6M allows a longer dosing interval than any other LAI antipsychotics, potentially reducing nonadherence and disease relapses. In future, an increase in the prescription rates of PP6M is expected and real-world efficacy and tolerability studies will be conducted.
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
    Journal, Adverse events:  Oral and long-acting injectable antipsychotic discontinuation and relationship to side effects in people with first episode psychosis: a longitudinal analysis of electronic health record data. (Pubmed Central) -  Dec 18, 2023   
    Among first prescribed antipsychotic medications, discontinuation occurred earlier with haloperidol [hazard ratio (HR)?=?2.78, 95% CI?=?1.69-4.60] and quetiapine (HR?=?1.43, 95% CI?=?1.16-1.80) than with olanzapine...Among antipsychotics prescribed at any point during treatment, lurasidone (HR?=?1.40, 95% CI?=?1.10-1.78) and aripiprazole (HR?=?1.09, 95% CI?=?1.01-1.19) were associated with earlier discontinuation than olanzapine...Later treatment discontinuation associated with clozapine and PP1M could be related to the relative efficacy of these treatments. These findings merit consideration when selecting antipsychotic therapy for people with FEP.
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
    Clinical, Review, Journal:  Long-Acting Injectable Antipsychotic Treatment for Schizophrenia in Asian Population: A Scoping Review. (Pubmed Central) -  Sep 25, 2023   
    Paliperidone palmitate once-monthly injection (27/46) and risperidone LAI (14/46) were the most frequently investigated LAIs...Better adherence and lower relapse were observed in patients receiving LAIs from published evidence. Future research is warranted to better understand the comprehensive performance of LAI in specific population or context.
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
    Journal, HEOR:  Cost-utility analysis of using paliperidone palmitate in schizophrenia in China. (Pubmed Central) -  Aug 21, 2023   
    The probability sensitivity analysis (PSA) revealed that when the WTP thresholds were $12,756.55/QALY, the probability of PP1M and PP3M being cost-effective was 59.2% and 66.0%, respectively. From the Chinese healthcare system perspective, PP3M and PP1M are both more cost-effective compared to ER, and PP3M has notable cost-utility advantages over PP1M.
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Hafyera (paliperidone palmitate extended-release 6-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
    Clinical, Journal, HEOR, Cost-effectiveness, Cost effectiveness:  Cost-effectiveness analysis of monthly, 3-monthly, and 6-monthly long-acting injectable and oral paliperidone in adults with schizophrenia. (Pubmed Central) -  Aug 7, 2023   
    For patients with schizophrenia stabilized with paliperidone ER, switching to LAI formulations was not cost-effective, suggesting the high drug costs for LAI may not justify the improved quality of life within 5 years. Among LAI formulations, PP6M was cost-effective over PP1M and PP3M.
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
    Journal:  Switching from Monthly to Three-Monthly Long-Acting Injectable Paliperidone: A Survey on Subjective Satisfaction and Safety. (Pubmed Central) -  Jul 19, 2023   
    This descriptive, cross-sectional survey explored patient's satisfaction and perspectives on the advantages and disadvantages of switching from monthly to 3-monthly paliperidone while also reporting on perceived levels of safety with regard to the reducing dose regimen during the Covid-19 pandemic...In fact, only one patient discontinued PP3M at one year with the overall number of hospitalisations also reducing in the same period compared to the year before switching. Our findings add to the small, but growing, body of evidence supporting patient satisfaction and acceptance with the use of PP3M and may reinforce the use of less frequent LAIs in clinical practice to enhance individual experience and treatment persistence and decrease levels of stigmatisation.
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
    Journal:  Biodegradation of additive-free polypropylene by bacterial consortia enriched from the ocean and from the gut of Tenebrio molitor larvae. (Pubmed Central) -  Jul 10, 2023   
    Two bacterial consortia, designated as PP1M and PP2G, were enriched from the ocean and from the guts of Tenebrio molitor larvae...Furthermore, low molecular weight PP powder was more susceptible to bacterial degradation compared to amorphous PP pellets. This study provides a unique example of different types of additive-free PP degradation by different culturable bacteria from the ocean and insect guts as well as a feasibility of PP waste removal in different environments.
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
    Analyzing Demographic Variabilities Associated With Age of Diagnosis of Schizophrenia Among Patients in Controlled Clinical Trials (Hall B Foyer, Exhibition Level Moscone South) -  May 17, 2023 - Abstract #APA2023APA_973;    
    Our analysis differs from previous studies and finds that AOD for male and female patients are seen in a unimodal distribution as compared to previous literature that shows a bimodal and trimodal distribution. Our findings not only call for a re-evaluation of previous epidemiological understandings of AOD but may support future efforts in understanding the origins and typical clinical presentations of patients with newly developed symptomatology of schizophrenia as well as support clinicians
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
    Treatment Resistant Schizophrenia With Prominent Capgras Delusions in a Young Female With Early-Onset Schizophrenia (Hall B Foyer, Exhibition Level Moscone South) -  May 17, 2023 - Abstract #APA2023APA_951;    
    Our findings not only call for a re-evaluation of previous epidemiological understandings of AOD but may support future efforts in understanding the origins and typical clinical presentations of patients with newly developed symptomatology of schizophrenia as well as support clinicians Trials included Abilify, Risperdal, Prolixin, Haldol, and Clozaril; all of which had stabilized the patient in the past...B also received multiple long-acting injectables including Invega Sustenna, Haldol decanoate, and Prolixin decanoate...B
  • ||||||||||  aripiprazole / Generic mfg.
    Aripiprazole: Examining the Clinical Implications of D2 Affinity (Hall B Foyer, Exhibition Level Moscone South) -  May 17, 2023 - Abstract #APA2023APA_737;    
    Trials included Abilify, Risperdal, Prolixin, Haldol, and Clozaril; all of which had stabilized the patient in the past...B also received multiple long-acting injectables including Invega Sustenna, Haldol decanoate, and Prolixin decanoate...B She historically has had good response to oral and long-acting formulations of Risperidone and Paliperidone...Those that have proposed mechanisms typically refer to Aripiprazole
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
    New Onset of Bipolar Disorder Post Covid-19 Infection (Hall B Foyer, Exhibition Level Moscone South) -  May 17, 2023 - Abstract #APA2023APA_695;    
    Clinicians need to be aware that a patient can present with an acute manic episode post recent COVID-19 infection. Future research is necessary to understand the pathogenesis better.
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
    Catamenial Mood Episode Exacerbation in Bipolar I Disorder (Hall B Foyer, Exhibition Level Moscone South) -  May 17, 2023 - Abstract #APA2023APA_664;    
    Due to lack of effect, olanzapine was changed to risperidone 3mg/day on day 9 which was increased to 4mg/day. As the patient
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
    A Case Report of a Patient Who Required a Second Long-Acting Injectable Antipsychotic to Stabilize Him (Hall B Foyer, Exhibition Level Moscone South) -  May 17, 2023 - Abstract #APA2023APA_650;    
    RB is a 37-year-old African American male, single, unemployed, domiciled in supportive housing, with past psychiatric history of Schizophrenia and Cannabis Use Disorder, multiple prior psychiatric hospitalizations, and a forensic history, who was followed by an Assertive Community Treatment team and receiving 3-monthly Paliperidone Palmitate 819 mg (last given 3-4 weeks prior to presentation) and oral Risperidone...Risperidone was discontinued and Fluphenazine 5 mg twice daily was started...Currently treatment guidelines do not support antipsychotic polypharmacy regardless of the formulation of the regimen or address two or more LAIs for treatment of Schizophrenia. Our case offers an alternative on how to manage patients with breakthrough symptoms and simultaneously address issues of treatment non-adherence in the community.
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
    Is the Recommendation Against Paliperidone Palmitate (Hall B Foyer, Exhibition Level Moscone South) -  May 17, 2023 - Abstract #APA2023APA_516;    
    Our case offers an alternative on how to manage patients with breakthrough symptoms and simultaneously address issues of treatment non-adherence in the community. Despite risperidone and paliperidone
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
    Journal:  Effectiveness of SGA-LAIs on Clinical, Cognitive, and Social Domains in Schizophrenia: Results from a Prospective Naturalistic Study. (Pubmed Central) -  May 16, 2023   
    We estimated an overall improvement over time on the explored outcomes, without differences with respect to the type of LAI investigated, and with a global 16.4% dropout rate. Our findings suggest that switching from oral SGA to SGA-LAIs represents a valid and effective treatment strategy, with significant improvements on psychopathological, cognitive, social, and clinical variables for patients suffering from schizophrenia, regardless of the type of molecule chosen.
  • ||||||||||  paliperidone palmitate ER (LY03010) / Luye Group
    Trial completion:  Relative Bioavailability of LY03010 Compared to Listed Drug (clinicaltrials.gov) -  Apr 25, 2023   
    P1,  N=281, Completed, 
    Our findings suggest that switching from oral SGA to SGA-LAIs represents a valid and effective treatment strategy, with significant improvements on psychopathological, cognitive, social, and clinical variables for patients suffering from schizophrenia, regardless of the type of molecule chosen. Active, not recruiting --> Completed
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Hafyera (paliperidone palmitate extended-release 6-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
    Journal, HEOR:  Budget impact of introducing once-every-6-months paliperidone palmitate in US health care plans. (Pubmed Central) -  Mar 2, 2023   
    Aditya Raju was an employee of Xcenda at the time of the development and finalization of the manuscript, and Danmeng Huang is an employee of Xcenda, a health care consulting firm that was contracted by Janssen Scientific Affairs, LLC. Chih-Yuan Cheng is an employee of Janssen NV.